The impact of sofosbuvir/ledipasvir on chronic hepatitis C-infected paediatric patients: a Middle East single-centre experience by Mohammad Fadhil Ibraheem, Falah Kareem

Subjects: Get full text

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C by Zehui Yan, Ke Fan, Xiaohong Wang, Qing Mao, Guohong Deng, Yuming Wang

“…The purpose of this study was to assess the efficacy and safety of low-dose peg-IFN α-2a plus ribavirin on the treatment of patients with chronic hepatitis C virus (HCV) infection. Patients and Methods. …”
Get full text

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial) by Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin

“…Nowadays the question, whether pegylated interferon should be completely abandoned in the treatment of chronic hepatitis C (CHC) is still open. Beneficial interferon properties include: absence of mutagenic capacity for hepatitis C virus and drug interaction, stimulation of host immune response. …”
Get full text

The Relation between Obesity and Survival after Surgical Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma by Hiroki Nishikawa, Akira Arimoto, Tomoko Wakasa, Ryuichi Kita, Toru Kimura, Yukio Osaki

“…We aimed to investigate the relationship between obesity and survival in hepatitis C virus-(HCV-) related hepatocellular carcinoma (HCC) patients who underwent curative surgical resection (SR). …”
Get full text

Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance by M. Ghabril, R. C. Dickson, M. Krishna, R. Lloyd, J. Aranda-Michel, A. Keaveny, R. Satyanarayana, H. Bonatti

“…Background. Hepatitis C virus (HCV) nondetectability in the liver may predict a sustained viral response (SVR) in patients with an end of treatment response. …”
Get full text

Telaprevir Activity is unaffected by the Q80K Polymorphism in Hepatitis C virus Genotype 1a by Stephen Shafran

Get full text

The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing by Stephen D Shafran

“…Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. …”
Get full text

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting by Vijay Gayam, Amrendra Kumar Mandal, Mazin Khalid, Osama Mukhtar, Arshpal Gill, Pavani Garlapati, Mowyad Khalid, Mohammed Mansour

“…Direct-acting antiviral (DAA) drugs have been highly effective in the treatment of chronic hepatitis C (CHC) infection. We aim to evaluate the treatment response of Sofosbuvir based DAA in CHC patients with compensated liver cirrhosis as limited data exists in the real-world community setting. …”
Get full text

Looking back into the Hepatitis C Virus epidemic dynamics from Unnao, India through phylogenetic approach by Ajit Patil, Pallavi Vidhate, Sandip Patil, Amrita Rao, Swarali Kurle, Samiran Panda

Get full text

Caracterización de pacientes con Hepatitis C en el servicio de hemodiálisis. Cienfuegos 2019 by Lizette Rodríguez Fernández, Evelyn Delgado Rodríguez, Aitana Blanco Morejón, Daniela de la Caridad Cedeño Díaz, Jayce Díaz Díaz, Jesús Julián Guada Delgado

Subjects: “…hepatitis c…”
Get full text

An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver by Robert P Myers, Hemant Shah, Kelly W Burak, Curtis Cooper, Jordan J Feld

“…Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. …”
Get full text

Formulation Design and Cell Cytotoxicity of Curcumin-Loaded Liposomal Solid Gels for Anti-Hepatitis C Virus by Helmy Yusuf, Erlyn K. D. D. Novitasari, Ni L. W. Purnami, Adhe W. Mahbub, Retno Sari, Dwi Setyawan

“…Anti-inflammatory and anti-hepatitis C virus (HCV) activities have been associated with CUR. …”
Get full text

Antineutrophil Cytoplasmic Antibody Induction due to Infection: A Patient with Infective Endocarditis and Chronic Hepatitis C by Fareed B. Kamar, T. Lee-Ann Hawkins

“…We also summarize previously reported cases of ANCA positivity in the context of endocarditis and hepatitis C infections.…”
Get full text

Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) by I. Yu. Pirogova, N. B. Kovaleva, E. P. Patlusov, E. S. Radchenko

“…Overall 164 patients with hepatitis C viruses (HCV) genotypes 1, 2 and 3 in 4 medical centers received antiviral therapy. …”
Get full text

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C by L. Tang, M. Kamat, A. Shukla, M. Vora, C. Kalal, S. Kottilil, S. Shah

“…Background. Chronic hepatitis C infection is a major cause for liver failure and liver cancer and can be treated with highly effective all oral directly acting antiviral (DAA) drugs. …”
Get full text

Clinical role of endothelial dysfunction and hemostasis gene allelic variants in hepatitis C virus-associated cryoglobulinemia by M. V. Sokolova, Ye. Ye. Starostina, T. N. Krasnova, L. M. Samokhodskaya, T. P. Rozina, V. G. Avdeyev, M. G. Artemova, Ye. B. Yarovaya, N. A. Mukhin

“…To estimate the effect of carriage of endothelial dysfunction and hemostasis gene allelic variants on development of cryoglobulinemic vasculitis (CryoVas) and its clinical symptoms in patients with chronic hepatitis C (CHC). Material and methods. Original study included overall 72 patients with CHC and cryoglobulinemia: 21 patients had CryoVas, 51 - CHC without vasculitis. …”
Get full text

Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C by Louis WC Liu, George Tomlinson, Tony Mazzulli, Alison Murray, Jenny Heathcote

“…BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection with interferon alpha-2b and ribavirin is costly in terms of side effects, medical resources and drug costs. …”
Get full text

Unraveling the intricate relationship between oral lichen planus and hepatitis C virus: A comprehensive exploration by Suryawanshi Hema, Hande Alka, Dasari Arun Kumar, Veeraraghavan Vishnu Priya, Sahu Manisha, Patil Santosh R

Get full text

Lymphoma-Associated Monoclonal Cryoglobulinemic Glomerulonephritis and Relationship with Hepatitis C Virus Infection: A Case Report by Sangeeta Mutnuri, Hania Kassem, John Badalamenti, You-Wen Qian, Christopher Marquez, Marjan Afrouzian

“…We report a case of type I cryoglobulinemic glomerulonephritis in a patient with chronic hepatitis C who presented with acute renal failure. …”
Get full text

High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C by David N Moskovitz, Pooma Manoharan, E Jenny Heathcote

“…OBJECTIVES: Approximately 60% of patients with chronic hepatitis C treated with a combination of interferon (IFN) alpha-2b and ribavirin are nonresponders. …”
Get full text